ALKS - CIK 0001520262
Alkermes plc. trades as ALKS and has a market capitalization of $7.10 B, making it the #1141 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $1.48B, down 5.2% from the prior year and net income of $241.70M. This page tracks Alkermes plc. through 1,884 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Alkermes plc.'s revenue grew from $745.69M to $1.48B, a compound annual growth rate of 7.9%. Net profit margin expanded from -28.0% to 16.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade (amended) | 4/A | 2026-05-22 |
| Insider trade (amended) | 4/A | 2026-05-22 |
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting | Alkermes plc
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences | Alkermes plc
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia | Alkermes plc
Alkermes plc Reports First Quarter 2026 Financial Results | Alkermes plc
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes’ website at www.alkermes.com . The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.
The largest companies sharing Alkermes plc.'s SEC industry classification (pharmaceutical preparations).
Alkermes plc. (ALKS) has a market capitalization of $7.10 B as of 2026-05-29, ranking #1141 among US-listed companies.
Alkermes plc. reported revenue of $1.48B for fiscal year 2025, a decrease of 5.2% year over year.
Yes. Alkermes plc. reported net income of $241.70M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.